Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Drug Profile

Research programme: protein kinase inhibitors - Deciphera Pharmaceuticals

Alternative Names: DCC 2721; DCC-2157; DP-3407; DP-3429; DP-3556; DP-3590; DP-4178; DP-4610; DP-4904

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Colony stimulating factor inhibitors; Macrophage colony stimulating factor receptor antagonists; P38 mitogen-activated protein kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c met inhibitors; Proto oncogene protein c-kit inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal stromal tumours

Highest Development Phases

  • No development reported Cancer metastases; Gastrointestinal stromal tumours; Solid tumours
  • Discontinued Autoimmune disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Cancer-metastases in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-stromal-tumours in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top